Non-cystic Fibrosis Bronchiectasis Clinical Trial
Official title:
Evaluating Trikafta for the Treatment of Patients With Non-cystic Fibrosis Bronchiectasis (NCFBE)
Study participants with non-cystic fibrosis bronchiectasis will be given Trikafta for four weeks. The researchers will monitor clinical endpoints, quality of life, and weight. Additionally, cutaneous punch biopsy material will be collected from each participant to test cellular response to Trikafta.
Non-cystic fibrosis bronchiectasis (NCFBE) is a clinical syndrome characterized by abnormal dilatation of the airways, airflow obstruction, persistent cough, excessive sputum production and recurrent lung infections. In terms of pathophysiology, airway dilatation and other features are associated with impaired mucociliary clearance and failure to adequately expel bacteria and mucus secretions from the airways. These events contribute to persistent infection, inflammation, and further progressive airway damage, leading to diminished lung function and eventually may cause respiratory failure and death. The pathogenesis of NCFBE is complex, poorly understood, and is likely to vary depending on the underlying etiology and important modifying factors. Trikafta is approved for patients with cystic fibrosis (CF) carrying at least one copy of the common F508del variant or a number of other cystic fibrosis transmembrane conductance regulator (CFTR) mutations. Trikafta is a combination of three CF drugs, elexacaftor, ivacaftor, and tezacaftor, that helps CFTR proteins work more effectively. Patients with common forms of CF typically exhibit a robust pulmonary benefit from Trikafta within several days to a few weeks of initiating treatment. NCFBE is clinically and pathologically similar to certain features of cystic fibrosis lung disease. Patients with NCFBE are not approved for Trikafta, and do not have access to the drug. Based on a considerable body of evidence, the researchers believe: 1) cutaneous punch biopsy material, differentiated to airway epithelium, can be used to identify patients with NCFBE likely to benefit from drugs such as Trikafta, and 2) many patients with NCFBE have a disease likely to exhibit significant clinical improvement when treated with a drug such as Trikafta that activates CFTR-dependent ion transport, although neither of those notions has been adequately tested or proposed previously. This study is an open-label, single center trial of orally administered elexacaftor, tezacaftor and ivacaftor (Trikafta) that will enroll 30 patients with NCFBE. Study participants will have one known CFTR mutation and/or mildly elevated sweat chloride measurements. In this matter, the study will specifically and prospectively test induced pluripotent stem (iPS) cells taken from patients with NCFBE to determine in vitro thresholds for predicting CFTR rescue in vivo. Using iPS cells differentiated to exhibit a respiratory epithelial phenotype, this study will determine whether the cells can be used to predict FEV1 response among individuals with NCFBE who receive Trikafta. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01792440 -
The Sputum Colour Chart as a Predictor of Lung Inflammation and Proteolysis in Non-cystic Fibrosis Bronchiectasis
|
N/A | |
Completed |
NCT05523180 -
A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life
|
N/A | |
Completed |
NCT03218917 -
Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
|
Phase 2 | |
Completed |
NCT05495243 -
Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-CF Bronchiectasis With Excess Mucus and Cough
|
Phase 2 | |
Recruiting |
NCT06237348 -
Simeox Therapy at Home Versus Standard of Care in NCFB Patients With CMH
|
N/A | |
Completed |
NCT03056326 -
A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT02614300 -
The Role of Pulmonary Rehabilitation and Airways Clearance Techniques in the Multidisciplinary Management of Non CF Bronchiectasis
|
N/A | |
Recruiting |
NCT04322929 -
Roflumilast in Non-CF Bronchiectasis Study (2019)
|
Phase 2 | |
Completed |
NCT05369624 -
Exercise Capacity in Non-cystic Fibrosis Bronchiectasis After a Pulmonary Rehabilitation Home-based Program
|
N/A | |
Completed |
NCT04010799 -
A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis
|
Phase 1 | |
Completed |
NCT03428334 -
Roflumilast in Non-CF Bronchiectasis Study
|
Phase 2 | |
Recruiting |
NCT06164470 -
Impact of Support Groups for Patients With Non-Cystic Fibrosis Bronchiectasis
|
N/A | |
Completed |
NCT04656275 -
A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation
|
Phase 1 | |
Not yet recruiting |
NCT06151366 -
Early Detection of Pulmonary Exacerbations in Non-cystic Fibrosis Bronchiectasis
|
||
Completed |
NCT02081963 -
Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis
|
Phase 4 | |
Completed |
NCT02883101 -
The Effects of Pulmonary Rehabilitation in Patients With Non-cystic Fibrosis Bronchiectasis
|
N/A | |
Completed |
NCT01792427 -
Mortality in Non-cystic Fibrosis Bronchiectasis
|
N/A | |
Recruiting |
NCT04278040 -
Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis
|
Phase 2 | |
Completed |
NCT05006573 -
Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis
|
Phase 3 | |
Not yet recruiting |
NCT06352944 -
Procalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children
|